Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 19/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 1.00 |
| ▸ | MEN1 | O00255 | 1/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 1.00 |
| ▸ | ALOX15 | P16050 | 1/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 1/20 | 1.00 |
| ▸ | HTR1D | P28221 | 3/20 | 0.80 |
| ▸ | HTR1A | P08908 | 2/20 | 0.80 |
| ▸ | DRD2 | P14416 | 2/20 | 0.80 |
| ▸ | HTR1B | P28222 | 2/20 | 0.80 |
| ▸ | HTR2A | P28223 | 2/20 | 0.80 |
| ▸ | HTR2C | P28335 | 2/20 | 0.80 |
| ▸ | HTR1E | P28566 | 2/20 | 0.80 |
| ▸ | HTR1F | P30939 | 2/20 | 0.80 |
| ▸ | HTR7 | P34969 | 2/20 | 0.80 |
| ▸ | ADRA1B | P35368 | 2/20 | 0.80 |
| ▸ | DRD3 | P35462 | 2/20 | 0.80 |
| ▸ | HTR2B | P41595 | 2/20 | 0.80 |
| ▸ | HTR4 | Q13639 | 2/20 | 0.80 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.80 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29388800 | 1.00 | HTR6 (1.00) | HTR6KDM4EMEN1ALDH1A1ALOX15 | |
| Hydrochloric Acid SCHEMBL28262289 | 0.99 | HTR6 (0.98) | HTR6KDM4EMEN1ALDH1A1ALOX15 | |
| SCHEMBL6185112 | 0.93 | HTR6 (0.87) | HTR6KDM4EMEN1ALDH1A1ALOX15 | |
| Hydrochloric Acid SCHEMBL6188937 | 0.92 | HTR6 (0.85) | HTR6KDM4EMEN1ALDH1A1ALOX15 | |
| SCHEMBL6969769 | 0.90 | HTR6 (0.81) | HTR6KDM4EMEN1ALDH1A1ALOX15 | |
| SCHEMBL6970959 | 0.90 | HTR6 (0.81) | HTR6KDM4EMEN1ALDH1A1ALOX15 | |
| SCHEMBL6972493 | 0.89 | HTR6 (0.83) | HTR6KDM4EMEN1ALDH1A1ALOX15 | |
| SCHEMBL6982638 | 0.89 | HTR6 (0.80) | HTR6KDM4EMEN1ALDH1A1ALOX15 | |
| SCHEMBL29496165 | 0.89 | HTR6 (1.00) | HTR6KDM4EMEN1ALDH1A1ALOX15 | |
| SCHEMBL13683252 | 0.89 | HTR6 (0.80) | HTR6KDM4EMEN1ALDH1A1ALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 94 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0946539-B1 | SULPHONAMIDE DERIVATIVES, PROCESS FOR THEIR PREPARATION, AND THEIR USE AS MEDICAMENTS | SMITHKLINE BEECHAM PLC (GB) | 2003-08-13 | — | — | EP | claimed |
| US-20030069233-A1 | Sulphonamide derivatives, process for their preparation, and their use as medicaments | SMITHKLINE BEECHAM P.L.C. | 2003-04-10 | — | — | US | claimed |
| CN-1246116-A | Sulfonamide derivatives, process for their preparation and their use as medicaments | SMITHKLINE BEECHAM PLC (GB) | 2000-03-01 | — | — | CN | claimed |
| EP-0946539-A1 | SULPHONAMIDE DERIVATIVES, PROCESS FOR THEIR PREPARATION, AND THEIR USE AS MEDICAMENTS | SMITHKLINE BEECHAM PLC (GB) | 1999-10-06 | — | — | EP | claimed |
| WO-1998027081-A1 | SULPHONAMIDE DERIVATIVES, PROCESS FOR THEIR PREPARATION, AND THEIR USE AS MEDICAMENTS | SMITHKLINE BEECHAM PLC (GB) | 1998-06-25 | — | — | WO | claimed |
| US-20250367232-A1 | HALOGEN TREATMENT OF HEART ATTACK AND ISCHEMIC INJURY | HUTCHINSON FRED CANCER RES (US) | 2025-12-04 | — | — | US | disclosed |
| US-20240366627-A1 | SMALL MOLECULES FOR MOUSE SATELLITE CELL PROLIFERATION | PRESIDENT AND FELLOWS OF HARVARD COLLEGE | 2024-11-07 | — | — | US | disclosed |
| US-12016880-B2 | Halogen treatment of heart attack and ischemic injury | FRED HUTCHINSON CANCER CENTER (US) | 2024-06-25 | — | — | US | disclosed |
| EP-3104939-B1 | TREATMENT OF HEART ATTACK AND ISCHEMIC INJURY WITH SODIUM IODIDE | FRED HUTCHINSON CANCER CENTER (US) | 2024-05-01 | — | — | EP | disclosed |
| US-11963964-B2 | Small molecules for mouse satellite cell proliferation | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2024-04-23 | — | — | US | disclosed |
| US-20230035892-A1 | METHODS AND COMPOSITIONS FOR TREATING CANCER | FLAGSHIP PIONEERING, INC. | 2023-02-02 | — | — | US | disclosed |
| US-20220387483-A1 | USE OF IODIDE COMPOUNDS FOR THE TREATMENT AND PREVENTION OF CHEMOTHERAPY-ASSOCIATED CACHEXIA AND CARDIOTOXICITY | FARADAY PHARMACEUTICALS INC (US) | 2022-12-08 | — | — | US | disclosed |
| US-20070049576-A1 | NEUROGENESIS BY MUSCARINIC RECEPTOR MODULATION | BRAINCELLS, INC. (US) | 2007-03-01 | — | — | US | disclosed |
| EP-0946539-B1 | SULPHONAMIDE DERIVATIVES, PROCESS FOR THEIR PREPARATION, AND THEIR USE AS MEDICAMENTS | SMITHKLINE BEECHAM PLC (GB) | 2003-08-13 | — | — | EP | disclosed |
| US-6599904-B2 | 5-HT6 receptor antagonists are believed to be of potential use in the treatment of certain CNS disorders; cognitive memory enhancement | SMITHKLINE BEECHAM P.L.C. (GB) | 2003-07-29 | — | — | US | disclosed |
| US-20030069233-A1 | Sulphonamide derivatives, process for their preparation, and their use as medicaments | SMITHKLINE BEECHAM P.L.C. | 2003-04-10 | — | — | US | disclosed |
| US-6423717-B1 | NERVOUS SYSTEM DISORDERS | SMITHKLINE BEECHAM P.L.C. (GB) | 2002-07-23 | — | — | US | disclosed |
| CN-1246116-A | Sulfonamide derivatives, process for their preparation and their use as medicaments | SMITHKLINE BEECHAM PLC (GB) | 2000-03-01 | — | — | CN | disclosed |
| EP-0946539-A1 | SULPHONAMIDE DERIVATIVES, PROCESS FOR THEIR PREPARATION, AND THEIR USE AS MEDICAMENTS | SMITHKLINE BEECHAM PLC (GB) | 1999-10-06 | — | — | EP | disclosed |
| WO-1998027081-A1 | SULPHONAMIDE DERIVATIVES, PROCESS FOR THEIR PREPARATION, AND THEIR USE AS MEDICAMENTS | SMITHKLINE BEECHAM PLC (GB) | 1998-06-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030069233-A1 | Sulphonamide derivatives, process for their preparation, and their use as medicaments | TPMT, MPST, STS | HTR6 1537/4885KDM4E 1086/4885MEN1 1567/4885 |
| US-20240366627-A1 | SMALL MOLECULES FOR MOUSE SATELLITE CELL PROLIFERATION | MKI67, MYLK2, MYH2 | HTR6 4177/4885KDM4E 1110/4885MEN1 4412/4885 |
| US-11963964-B2 | Small molecules for mouse satellite cell proliferation | MKI67, MYLK2, MYH2 | HTR6 4177/4885KDM4E 1110/4885MEN1 4412/4885 |
| US-20070049576-A1 | NEUROGENESIS BY MUSCARINIC RECEPTOR MODULATION | CHRNB2, CHAT, CHRNB4 | HTR6 200/4885KDM4E 2095/4885MEN1 4080/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.